Skip Navigation Links.

Sun Pharmaceuticals Industries Ltd


BSE: 524715 | NSE: SUNPHARMA | ISIN: INE044A01036 
Market Cap: [Rs.Cr.] 59,024 | Face Value: [Rs.] 1
Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

 Discuss this stock

Board Meet

29-May-12 
Sun Pharmaceutical Industries Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 29, 2012, inter alia: 1. To consider and approve the audited financial results of the Company for the year ended March 31, 2012. 2. To consider the recommendation of payment of dividend on equity shares for the year ended March 31, 2012 subject to the approval of the shareholders at the ensuing Annual General Meeting. 
13-Feb-12 
Sun Pharmaceutical Industries Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 13, 2012, inter alia, to consider and take on record the un-audited financial results of the Company for the third quarter / nine months ended December 31, 2011 (Q3). 
13-Nov-11 
Sun Pharmaceutical Industries Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on November 13, 2011, inter alia, to consider and take on record the un-audited financial results of the Company for the second quarter / half year ended September 30, 2011 (Q2). 
28-Jul-11 
Sun Pharmaceutical Industries Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on July 28, 2011, inter alia, to consider and take on record the un-audited financial results of the Company for the first quarter ended June 30, 2011 (Q1). 
28-May-11 
Sun Pharmaceutical Industries Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 28, 2011, inter alia, 1. To consider and approve the audited financial results of the Company for the year ended March 31, 2011. 2. To consider the recommendation of payment of dividend on equity shares for the year ended March 31, 2011 subject to the approval of the shareholders at the ensuing Annual General Meeting. Sun Pharmaceutical Industries Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 28, 2011, inter alia, has recommended payment of dividend of Rs. 3.50 (Rupees Three and paise fifty) per equity share of Re. 1/- each of the Company for the year ended March 31, 2011 subject to the approval of the members at the ensuing Annual General Meeting of the Company. The dividend, if declared by the shareholders will be paid on or after about September 20, 2011. (As Per BSE Announcement Website dated on 28.05.2011) 

AGM

16-Sep-11
Sun Pharmaceutical Industries Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from September 06, 2011 to September 16, 2011 (both days inclusive) for the purpose of Payment of Dividend & 19th Annual General Meeting (AGM) of the Company to be held on September 16, 2011. Sun Pharmaceutical Industries Ltd has informed BSE that the 19th Annual General Meeting (AGM) of the Company was held on September 16, 2011. 1. The Balance Sheet as at March 31, 2011 along with the Profit and Loss Account for the year ended on that date and the Reports of Directors & Auditors thereon were received, considered and adopted unanimously as per Item No.1 of the Notice dated May 28, 2011 calling the AGM. 2. The Members also unanimously approved the payment of dividend at the rate of Rs. 3.50 per equity share of Re. 1/- each as recommended by the Board of Directors at their Meeting held on May 28, 2011 on 1007,010,525 (One Thousand Seven Million Ten Thousand Five Hundred Twenty Five) Equity Shares of Re. 1/- each amounting to Rs. 3,524,536,837.50 (Rupees Three Billion, Five Hundred and Twenty Four Million ,Five Hundred Thirty Six Thousand Eight Hundred Thirty Seven and Paise Fifty only) as Dividend for the year ended March 31, 2011 after excluding an amount of Rs. 100,000,005/- (Rupees One Hundred Million and Five only) on 28,571,430 (Twenty Eight Million Five Hundred Seventy One Thousand Four Hundred and Thirty) Equity Shares of Re. 1/- each for which certain shareholders have waived/ foregone their right to receive the dividend for the year ended March 31, 2011 as per Item No.2 of the Notice dated May 28, 2011. 3. The Members unanimously approved the re-appointment of Shri. Dilip S. Shanghvi as a Director of the Company, who retired by rotation and being eligible, offered himself for re-appointment as per Item No.3 of the Notice dated May 28, 2011. 4. The Members unanimously approved the re-appointment of Shri. Sailesh T. Desai as a Director of the Company, who retired by rotation and being himself for re-appointment as per Item No.4 of the Notice dated May 28, 2011. 5. The Members unanimously approved the re-appointment of Shri S. Mohanchand Dadha as a Director of the Company, who retired by rotation and being eligible, offered himself for re-appointment as per Item No.5 of the Notice dated May 28, 2011. 6. The Members unanimously approved the re-appointment of M/s. Deloitte Haskins & Sells, Chartered Accountants, Mumbai, as the Statutory Auditors of the Company to hold office from conclusion of this Annual General Meeting till the conclusion of the next Annual General Meeting and authorised the Board to fix their remuneration as per Item No.6 of the Notice dated May 28, 2011. 7. The Members, as and by way of a special resolution, unanimously approved the remuneration in the form of annual fee, sitting fees per meeting of the Board of Directors and any committee thereof and an annual discretionary bonus by Taro Pharmaceutical Industries Ltd (TARO), a subsidiary of the Company, to Mr. Aalok D. Shanghvi, who is a relative of a Director, as Non-Executive Director of TARO upto USD 650,000/- per annum in addition to sifting fees per meeting of the Board of Directors and any committee thereof and an annual discretionary bonus by TARO exclusive of reimbursement of any expenses for a period of four years, effective as of the date of his appointment under TARO, i.e., September 20, 2010 subject to the approval of the Central Government and such other authorities as may be required and the increase in upper limit of remuneration payable to Mr. Aalok D. Shanghvi, relative of a Director, as Asst. Product Manager in our Company from April 1, 2011 for the remaining period upto March 31, 2014 upto a maximum remuneration (excluding reimbursement of expenses, if any) of Rs. 1,00,00,000/- (Rupees One Crore only) per annum, subject to the approval of the Central Government and such other authorities as may be required as per Item No.7 of the Notice dated May 28, 2011. (As Per BSE Annoncement Website Da ted on 20/09/2011) Sun Pharmaceutical Industries Ltd has submitted to BSE a copy of 19th AGM speech. (As Per BSE Announcement Dated on 26.09.2011) 
24-Sep-10
Sun Pharmaceutical Industries Ltd has informed BSE that the 18th Annual General Meeting (AGM) of the members of the Company will be held on September 24, 2010. 
11-Sep-09
AGM 11.09.2009 Source: Annual Report Sun Pharmaceutical Industries Ltd has informed BSE that the members at the 17th Annual General Meeting (AGM) of the Company held on September 11, 2009, inter alia, to transact following Business: 1. Adoption of the Balance Sheet as at March 31, 2009 along with the Profit and Loss Account for the year ended on that date and the Reports of Directors & Auditors thereon. 2. Approved the payment of dividend at the rate of Rs.13.75 per equity share of Rs.5 /- each as recommended by the Board of Directors at their Meeting held on May 30, 2009 on 207,116,391 (Two Hundred Seven Million One Hundred Six teen Thousand Three Hundred Ninety One) Equity Shares of Rs.5/- each amounting to Rs. 2847,850,376.25 (Rupees Two Thousand Eight Hundred Forty Seven Million Eight Hundred Fifty Thousand Three Hundred Seventy Six and Raise Twenty Five only) as Dividend for the year ended March 31, 2009. 3. Re-appointment of Mr. Dilip S. Shanghvi & Mr. Keki M Mistry as Directors of the Company, who retired by rotation and being eligible, offered themselves for re-appointment. 4. Re-appointment of M/s. Deloitte Haskins & Sells, Chartered Accountants, Mumbai as the Statutory Auditors of the Company to hold office from the conclusion of this Annual General Meeting till the conclusion of the next Annual General Meeting of the Company on remuneration, terms & conditions. 5. Appointment of Mr. Khyati S Valia, relative of Mr. Shri. Sudhir V Valia as Management Trainee in the Company for a period of five years from April 01, 2010, on remunerations, terms & conditions. (As Per BSE Announcement Website dated on 14.09.2009) 
06-Sep-08
Sun Pharmaceuticals Industries Ltd has informed the Exchange that the Annual General Meeting of the Company is scheduled to be held on September 06, 2008. Sun Pharmaceutical Industries Ltd has informed BSE that the members at the 16th Annual General Meeting (AGM) of the Company held on September 06, 2008, inter alia, have transacted the following businesses: 1. Adoption of the Balance Sheet as at March 31, 2008 along with the Profit and Loss Account for the year ended on that date and the Reports of Directors & Auditors thereon. 2. Confirmation of payment of pro-rate Interim Dividend on Preference Shares @ 6% p.a. on 13,740,030 - 6% Cumulative Redeemable Preference Shares of Re 1/- each on its paid-up value, for the year ended March 31, 2008. Approved the payment of dividend at the rate of Rs 10.50 per equity share of Rs 5/- for the year ended March 31, 2008 after excluding an amount of Rs 100,000,005/- on 9,523,810 equity share of Rs 5/- each for which certain shareholders have waived / forgone their right to receive the dividend for the year ended March 31, 2008as per item no 2 of the notice dated July 14, 2008. 3. Re-appointment of Mr. S Mohanchand Dadha & Mr. Shaliesh T Desai as Directors of the Company, who retired by rotation and being eligible, offered themselves for re-appointment. 4. Re-appointment of M/s. Deloitte Haskins & Sells, Chartered Accountants, Mumbai as the Statutory Auditors of the Company to hold office from the conclusion of this Annual General Meeting till the conclusion of the next Annual General Meeting of the Company on remuneration, terms & conditions. 5. Re-classification of the authorised share capital of the Company amounting to Rs 1475.0 Million (Rupees One Thousand Four Hundred Seventy Five Million only) and Preference Share Capital of Rs 25.0 Million (Rupees Twenty Five Million only) to Equity Share Capital of Rs 1500.0 Millions (Rupees One Thousand Five Hundred Million only) and also approved the alteration of Clause V of Memorandum of Association of the Company. 6. Alteration of Clause 4 of the Articles of Association of the Company giving effect to re-classification of authorised share capital of the Company. 7. Re-appointment of Mr. Sudhir V Valia & Mr. Shailesh T Desai, as the Whole-time Director of the Company for a further period of five years from April 01, 2009, on remuneration terms & conditions. 8. Appointment of Mr. Alok D Shanghvi, relative of Mr. Dilip S Shanghvi as Product Executive in the Company for a period of five years from April 01, 2009, on remunerations, terms & conditions. (As per BSE Announcement dated on 08/09/2008) 
05-Sep-07
A.G.M 05/09/2007 Sun Pharmaceutical Industries Ltd has informed BSE that the members at the 15th Annual General Meeting (AGM) of the Company held on September 05, 2007, inter alia, have transacted the following businesses: 1. Adoption of the Balance Sheet as at March 31, 2007 along with the Profit and Loss Account for the year ended on that date and the Reports of Directors & Auditors thereon. 2. (a) Confirmation of payment of Interim Dividend on Preference Shares @ 6% p.a. on 13,740,030 - 6% Cumulative Redeemable Preference Shares of Re 1/- each on its paid-up value, as final dividend for the year ended March 31, 2007. (b) Confirmation of payment of interim dividend at the rate of Rs 6.75 per equity share on 192,537,780 Equity Shares of Rs 5/- each, as final dividend for the year ended March 31, 2007. 3. Re-appointment of Mr. Sudhir V Valia & Mr. Ashwin S Dani as Directors of the Company. 4. Re-appointment of M/s. Deloitte Haskins & Sells, Chartered Accountants, Mumbai as the Statutory Auditors of the Company to hold office from the conclusion of this Annual General Meeting till the conclusion of the next Annual General Meeting of the Company on remuneration, terms & conditions. 5. Re-classification of the authorised share capital of the Company amounting to Rs 1500.0 Million from Equity Share Capital of Rs 1273.5 Million and Preference Share Capital of Rs 226.5 Million to Equity Share Capital of Rs 1475.0 Millions and Preference Share Capital of Rs 25.0 Million and also approved the alteration of Clause V of Memorandum of Association of the Company. 6. Alteration of Clause 4 of the Articles of Association of the Company giving effect to re-classification of authorised share capital of the Company. 7. Re-appointment of Mr. Dilip S Shanghvi as the Chairman & Managing Director of the Company for a further period of five years from April 01, 2008, on remuneration terms & conditions. 8. Payment of remuneration by way of commission to Non-Executive Directors of the Company (other than the Managing Director and / or Whole Time Directors) over a period of five years from the financial year ending on March 31, 2008 up to and including financial year of the Company ending as on March 31, 2012. (As Per BSE Announcement Website Dated on 06/09/2007) 

EGM

28-Jul-07
Sun Pharmaceutical Industries Ltd has informed BSE that an Extra Ordinary General Meeting (EGM) of the members of the Company will be held on July 28, 2007, inter alia, to transact the following business: 1. To issue, offer and allot from time to time in one or more tranches and in consultation with the Lead Managers and/or Underwriters and/or other Advisors, Convertible Bonds, Debentures and / or Securities convertible into Equity Shares at the option of the Company or the holders thereof and / or securities with or without detachable warrants with or without right exercisable by the warrant holder to convert or subscribe to Equity Shares and / or Bonds or Foreign Currency Convertible Bonds or Securities through Global Depository Receipts, American Depository Receipts or any other Deposit Receipts or bonds or any other Securities or Financial Derivatives ("the Securities") to such Indian or Foreign Institutional Investors / Foreign Mutual Funds / Overseas Corporate Bodies / Foreigners / other Foreign parties/ Indian Financial Institutions / Companies / individuals / other persons or investors, whether or not they are members of the Company and / or by any one or more or a combination of the above modes / methods or otherwise by offering the Securities in the international market comprising one or more countries or domestic market or in any other approved manner through Prospectus and / or Offering Letter or Circular and / or on private placement basis as may be deemed appropriate by the Board such offer, issue and allotment to be made at such time or times at such issue price, face value, premium amount on issue / conversion of securities / exercise of warrants / redemption of Securities, rate of interest, redemption period, listing on one or more stock exchange in India and / or abroad and in such currency and in such manner and on such terms and conditions as the Board may think fit, for an aggregate amount (inclusive of such premium as may be fixed on the securities) not exceeding Rs 35,000 Million with power to the Board to settle details as to the form and terms of issue of the Securities, and all other terms, conditions and matters connected therewith or difficulties arising therefrom, subject to necessary provisions & approvals. 2. To borrow from time to time any sum or sums of monies which together with the monies already borrowed by the Company (apart from temporary loans obtained or to be obtained from the Company's bankers in the ordinary course of business) exceed the aggregate paid up capital of the Company and its free reserve, that is to say reserve not set apart for any specific purpose provided that the total amount so borrowed by the Board shall not at any time exceed the limit of Rs 50,000 Million, subject to necessary provisions & approvals. 3. To make loan(s) and/or give any guarantee(s)/provide any security(ies) in connection with loan(s) made to and to make investments in Shares, Debentures and / or any other Securities of other body corporates, whether Indian or overseas and / or in various schemes of Mutual Funds or such other funds, in their absolute discretion deem beneficial and in the interest of the Company in excess of 60% of the paid up Share Capital and Free Reserves of the Company or 100% of Free Reserves of the Company whichever is more, as prescribed under section 372A of the Companies Act, 1956 from time to time, in one or more tranches, upto maximum amount of Rs 50,000 Million notwithstanding that investments along with Company's existing loans or guarantee / security or investments shall be in excess of the limits prescribed under Section 372A aforesaid, subject to necessary provisions & approvals. Sun Pharmaceutical Industries Ltd has informed BSE that the members at the Extra Ordinary General Meeting (EGM) of the Company held on July 28, 2007, inter alia, have accorded to the following: 1. Authority to the Board to issue, offer and allot from time to time in one or more tranches, Convertible Bonds, Debentures and/or Securities convertible in to Equity Shares at the option of the Company or the holders thereof and/or securities with or without detachable warrants with or without right exercisable by the warrant holder to convert or subscribe to Equity Shares and/or Bonds or Foreign Currency Convertible Bonds or securities through Global Depository receipts, American Depository Receipts or any other Deposit Receipts or Bonds or any other Securities or Financial Derivatives in such currency, in such other manner and on such terms and conditions in accordance with the provisions of Section 81(1A) of the Companies Act, 1956 for an aggregate amount not exceeding Rs 35,000 Million. 2. Authority to the Board to borrow from time to time any sum or sums of monies which together with the monies already borrowed by the Company (apart from temporary loans obtained or to be obtained from the Company's bankers in the ordinary course of business) exceed the aggregate paid up capital of the Company and its free reserve as prescribed under Section 293(1)(d) of the Companies Act, 1956 and up to a maximum limit of Rs 50,000 Million. 3. Authority to the Board to make investments in shares, debentures and/or any other securities in excess of 60% of the paid-up share capital and free reserves of the Company or 100% of Free Reserves of the Company whichever is more, as prescribed under Section 372A of the Companies Act, 1956 and up to a maximum amount of Rs 50,000 Million. (As Per BSE Announcement Website Dated on 28/07/2007) 
06-Jun-06
Sun Pharmaceutical Industries Ltd has informed BSE that pursuant to the order made by the Hon'ble High Court of Gujarat at Ahmedabad: 1. A meeting of the equity shareholders of the Company will be held on June 06, 2006, for the purpose of considering and if thought fit, approving with or without modification(s), the arrangement embodied in the Scheme of Arrangement between the Company and the equity shareholders of the Company in the nature of demerger and transfer of Innovative Research and Development Business of the Company to Sun Pharma Advanced Research Company Ltd. 2. A meeting of the preference shareholders of the Company will be held on June 06, 2006, for the purpose of considering and if thought fit, approving with or without modification(s), the arrangement embodied in the Scheme of Arrangement between the Company and the preference shareholders of the Company in the nature of demerger and transfer of Innovative Research and Development Business of the Company to Sun Pharma Advanced Research Company Ltd. 3. A meeting of the FCCB holders of the Company will be held on June 06, 2006, for the purpose of considering and if thought fit, approving with or without modification(s), the arrangement embodied in the Scheme of Arrangement between the Company and the FCCB holders of the Company in the nature of demerger and transfer of Innovative Research and Development Business of the Company to Sun Pharma Advanced Research Company Ltd. The Company has informed that the Court Convened Meetings of the Equity Shareholders, Preference Shareholders, Secured Creditors, Unsecured Creditors and Foreign Currency Convertible Bond (FCCB) holders of the Company held on June 06, 2006, have unanimously approved the Scheme of Arrangement between the Company and Sun Pharma Advanced Research Company Ltd (SPARC) in the nature of demerger and transfer of Innovative Research and Development (Including New Drug Delivery Systems) Business / Unit of the Company to SPARC with effect from April 01, 2006. (As per BSE Bulletin Dated on 07/06/2006) 
04-Apr-05
EGM 04/04/2005 A meeting of the Equity & Preference Shareholders of the company as per the directives of othe Honble High Court of Gujarat at Ahmedabad to consider and if thought fit, to approve with or without modification(s), the arrangement embodied in the Scheme of Amalgamation of nPhlox Pharmaceuticals Ltd with the Company. 
08-Feb-05
EGM 08/02/2005 To seek members approval for appointment of M/s Deloitte Haskins & Sells, Chartered Accountants, Mumbai as the Statutory Auditors of the Company to fill up the casual vacancy caused by the resignation of M/s Price Waterhouse, Chartered Accountants, Mumbai. Sun Pharmaceuticals Industries Ltd has informed the Exchange that an EGM of the equity shareholders will be held on February 08,2005 for seeking the equity shareholders' approval to appoint of M/s. Deloitte Haskins & Sells, Chartered Accountants, Mumbai, as Statutory Auditors of the company to fill up the casual vacancy caused by the resignation of M/s. Price Waterhouse, Chartered Accountants,Mumbai. (As per NSE Bulletin dated on 17/01/2005) The Company has informed that the members at the Extra Ordinary General Meeting of the Company held on February 08, 2005 have unanimously approved the appointment of Messrs. DeloitteHaskins & Sells, Chartered Accountant, Mumbai, in the casual vacancy caused by the resignation of Messrs. Price Waterhouse, Chartered Accountants, Mumbai to hold office upto the conclusion of adjourned Twelfth Annual General Meeting of the Company at a remuneration to be fixed by the Board of Directors of the Company. (As per BSE bulletin dated on 08/02/2005) 
24-Jan-05
Surya Pharmaceutical Limited has informed the Exchange that an Extraordinary General Meeting of the Members of the Company will be held on January 24, 2005, to transact the following business as special business:1)Increase the Authorised Share Capital of the Company . 2)To issue Zero Coupon Share Warrants convertible into equity shares. 

Peer Comparison

Company Market Cap
(Rs. in Cr.) 		P/E (TTM)
(x) 		P/BV (TTM)
(x) 		EV/EBIDTA
(x) 		ROE
(%) 		ROCE
(%) 		D/E
(x)
Sun Pharma.Inds. 59,024.02 36.91 8.84 29.33 22.3 23.3 0.01
Dr Reddy's Labs 28,898.96 31.67 4.30 22.23 15.0 15.2 0.17
Cipla 24,889.90 22.14 3.32 18.79 15.4 17.9 0.04
Ranbaxy Labs. 22,222.51 17.79 11.55 0.00 0.0 0.0 1.22
Cadila Health. 15,284.86 23.25 6.00 21.79 32.9 27.5 0.31
Glenmark Pharma. 9,637.92 36.32 4.41 24.56 11.3 11.9 0.51
Wockhardt 8,617.31 29.96 71.71 39.85 0.0 0.0 3.18
Piramal Health 7,302.32 55.83 0.66 0.33 4.2 6.1 0.07
Torrent Pharma. 5,414.83 14.93 4.15 11.43 29.5 25.9 0.55
Biocon 4,322.00 16.91 2.06 11.21 26.2 26.8 0.10
Ipca Labs. 4,270.28 15.69 4.05 10.26 26.5 25.1 0.51
Strides Arcolab 3,982.81 61.55 2.94 16.20 5.1 5.7 0.97
Aurobindo Pharma 3,357.84 10.43 1.31 8.01 26.5 19.7 0.95
Matrix Labs. 3,273.19 8.13 2.00 0.00 28.9 27.4 0.52
Fres.Kabi Onco. 2,187.12 83.79 4.04 16.45 9.5 10.8 0.58

Futures & Options Quote

 
Expiry Date
575.50 4.20  (0.7%)
Instrument: FUTSTK
Expiry Date: 31 May 2012
Open Price: 574.00
Average Price: 575.97
No. of Contracts Traded: 220,500
Open Interest: 1,666,000
Underlying: SUNPHARMA
Market Lot: 500
Previous Close: 571.30
Day’s High | Low: 578.75 | 573.70
Turnover (Cr.): 12.70
Open Int. Change: 28,000.00 (1.7% )
View detailed F& O quotes >>

Key Information

Key Executives:

Dilip S Shanghvi , Chairman & Managing Director 

Sudhir V Valia , Whole-time Director 

Sailesh T Desai , Whole-time Director 

S Mohanchand Dadha , Director 

Company Head Office / Quarters:
Sun Pharma Advanced Res.Centre,
Tandalja,
Vadodara,
Gujarat-390020
Phone : 91-265-5515500/5515600
Fax : 91-265-2354897
E-mail : secretarial@sunpharma.com
Web : http://www.sunpharma.com
Registrars:
Link Intime India Pvt Ltd
C-13 Pannalal Silk
Mills Cmpd LBS Marg
Bhandup West
Mumbai - 400 078

Fund Holding

 

Calendar

May-2012
M T W T F S S
21 22 23 24 25 26 27
IPO
listNo IPO today
Economic Events
list U. of Michigan Confidence
list Italian Hourly Wages (MoM)
Results
list Reliance Infra. | Crompton Greaves | ITC | Guj Fluorochem